Orexo AB
STO:ORX
Net Margin
Orexo AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| SE |
|
Orexo AB
STO:ORX
|
690.1m SEK |
-35%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
737B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
374.8B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
205B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
191.4B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
160.3B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
204.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
185.4B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.6B USD |
13%
|
Orexo AB
Glance View
Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. The company is headquartered in Uppsala, Uppsala and currently employs 121 full-time employees. The company went IPO on 2005-11-09. The company focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The firm has four commercialized products, several projects developed in partnership, as well as three development programs. The firm's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The firm operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Orexo AB's most recent financial statements, the company has Net Margin of -35.2%.
You don't have any saved screeners yet